BIOLASE to market its Waterlase MD products in China

NewsGuard 100/100 Score

BIOLASE Technology, Inc. (NASDAQ: BLTI) today announced that it finalized three regional distribution agreements in the People's Republic of China. This announcement follows the Company's August 12, 2009, announcement that it had received regulatory approval to market its Waterlase MD™ products in China.

"Three regional agreements were signed in China with partners who have gained our strong confidence," David M. Mulder, Chief Executive Officer said. The first agreement was with Shanghai Haopu Medical Instruments Co., Ltd. (Haopu) for primarily the eastern Chinese provinces and municipalities of Anhui, Fujian, Henan, Jiangsu, Jiangxi, Shandong, Shanghai and Zhejiang. Haopu is a dynamic young company with eight years of business development experience and a good reputation for customer satisfaction from their service and clinical education programs in the East China region. Mulder continued, "Haopu worked with us closely on the Chinese registration process and we very much appreciate their assistance, and look forward to moving forward together."

The second agreement is with Beijing E-Maxdent Company (E-Maxdent), covering primarily the Northern provinces and municipalities of Beijing, Gansu, Hebei, Heilongjian, Jilin, Liaoning, Qinghai, Shaanxi, Tianjin, Nei Mongol, Ningxia, Tibet and Xinjiang. Mulder said, "The principals of E-Maxdent are all dentists. They share our passion for delivering better dentistry around the world. They currently distribute other high tech dentistry equipment in North China and felt the addition of the leading dental laser brand in the world was critical to that offering."

The third agreement was with Advanced Medical Technology China Ltd. (Advanced) for primarily the southern provinces and municipalities of Guangdong, Guangxi, Hainan, Yunnan, Hunan, Guizhou, Sichuan, Chongqing and Hubei. Mulder continued, "We have worked with the principals of Advanced very successfully in Hong Kong, and they have pre-established operations on the mainland where we are very excited about extending our partnership."

"We have already started working on some initial demonstration unit orders, training and marketing plans. We expect a six- to nine-month ramp-up period and look forward to a promising future in China," Mulder concluded. Contact information for the three distributors is currently being added to the Company's website at www.biolase.com.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Advances and hurdles: The impact of AI on oncology care efficiency and mortality rates